Page 85 of 102 FirstFirst ... 35757677787980818283848586878889909192939495 ... LastLast
Results 841 to 850 of 1011

Thread: Spinal Cord Injury Articles Posted by Manouli

  1. #841
    InVivo Therapeutics Holdings (NASDAQ:NVIV)
    Intraday Stock Chart
    Today : Tuesday 8 September 2015
    /p.php?pid=qkchartp.php?pid=qkchart
    - Communicates Intent to Incorporate Pilot Study into Pivotal Probable Benefit Study -
    InVivo Therapeutics Holdings Corp. (NVIV) today announced that the fifth patient has been enrolled in the company’s ongoing pilot study of its investigational Neuro-Spinal Scaffold™ implant in patients with acute thoracic spinal cord injury at the Keck Hospital of University of Southern California (USC) in Los Angeles.
    Patrick Hsieh, M.D., Principal Investigator at this site, performed the fifth-ever Neuro-Spinal Scaffold implantation approximately 69 hours after the injury occurred.
    “Enrolling the fifth patient in our first clinical study is a momentous milestone for the company, and we are pleased this accomplishment came ahead of previous guidance,” said Mark Perrin, InVivo’s CEO and Chairman. “We are in productive discussions with the FDA regarding the transition to the pivotal probable benefit study, and our plan is to incorporate the pilot study into the pivotal probable benefit study. We expect to use this single study as the basis for a Humanitarian Device Exemption (HDE) application, which would allow us to dramatically reduce the time to approval and commercialization.”
    Mr. Perrin continued, “While we are discussing plans with the FDA for the pivotal probable benefit study and the incorporation of the pilot study, we intend
    read..

    http://ih.advfn.com/p.php?pid=nmona&article=68437937

  2. #842
    Public Release: 8-Oct-2015
    Kazan researchers compare direct gene vs blood cell-mediated therapy of spinal cord injury
    Experimental study
    Kazan Federal University

    Spinal cord injury (SCI) leads to complex pathological changes that include the death of neurons and glial cells and degeneration of nerve fibers.
    One promising approach for preventing neurodegeneration involves locally treating the site of injury. One of such factors particularly suitable for SCI treatment is glial cell-derived neurotrophic factor (GDNF).
    Previous studies of KFU researchers on direct gene therapy for spinal cord injuries indicated that the treatment resulted in the preservation of nervous tissue and functional recovery. Similarly, cell-based gene delivery has been shown to promote the growth of motor axons after partial and complete spinal cord transections.
    The group of scientists from the Institute of Fundamental Medicine and Biology at Kazan Federal University developed special umbilical cord blood mononuclear cells, the main positive action of which was that they facilitated targeted delivery of the therapeutic molecules to motor neurons and thereby prolonged their survival. UCB-MCs have been used for gene delivery because of their suitability for low immunogenicity, accessibility and ease of production and storage, and because of the lack of legal, ethical and religious concerns related to using these cells.
    read...
    http://www.eurekalert.org/pub_releas...-krc100815.php

  3. #843
    ⦁ Researchers compare direct gene vs. blood cell-mediated therapy of spinal cord injury
    One promising approach for preventing neurodegeneration involves locally treating the site of injury. One such approach particularly suitable for SCI treatment is glial cell-derived neurotrophic factor (GDNF).
    Previous studies of KFU researchers on direct gene therapy for spinal cord injuries indicated that the treatment resulted in the preservation of nervous tissue and functional recovery. Similarly, cell-based gene delivery has been shown to promote the growth of motor axons after partial and complete spinal cord transections.
    The group of scientists from the Institute of Fundamental Medicine and Biology at Kazan Federal University developed special umbilical cord blood mononuclear cells, the main positive action of which was that they facilitated targeted delivery of the therapeutic molecules to motor neurons and thereby prolonged their survival. UCB-MCs have been used for gene delivery because of their suitability for low immunogenicity, accessibility and ease of production and storage, and because of the lack of legal, ethical and religious concerns related to using these cells.
    A rat SCI model was used to examine the efficacy of the two methods.
    read...
    http://medicalxpress.com/news/2015-1...py-spinal.html

  4. #844
    Asterias Biotherapeutics to Begin Dose Escalation in the SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
    October 20, 2015
    No Serious Adverse Events Reported with Initial AST-OPC1 Dose
    First Patient in Initial Dose Cohort Shows Neurological Improvement
    Menlo Park, Calif. October 20, 2015— Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort. Recruitment for the second cohort will begin immediately, with a planned enrollment of five patients who will each receive 10 million cells of AST-OPC1 (oligodendrocyte progenitor cells).
    The SCiStar Study is a Phase 1/2a clinical trial evaluating the safety and activity of escalating doses of AST-OPC1 in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). The three patients in the first cohort were administered a low dose of 2 million AST-OPC1 cells and have completed at least 30 days of follow up for safety. The results of the trial continue to support a positive safety profile for AST-OPC1, with no serious adverse events observed to date in any of the three treated patients.
    read...
    http://asteriasbiotherapeutics.com/a...l-cord-injury/

  5. #845
    News Release
    phoenix.zhtml?c=86230&p=irol-newsArticle_print&ID=2111834 phoenix.zhtml?c=86230&p=irol-newsArticle_print&ID=2111834View printer-friendly version
    << Back
    StemCells, Inc. Announces Webcast to Discuss Interim Results From the First Cohort in Its Phase II Study in Cervical Spinal Cord Injury
    NEWARK, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, will host a webcast to discuss the six-month interim results from the first cohort in its Phase II PathwayTM Study in cervical spinal cord injury. The Company will also provide a progress update on the second 40-patient cohort which is currently enrolling patients.

    http://investor.stemcellsinc.com/pho...cle&ID=2111834

  6. #846
    I need to hear some good news, so I got this article and I feel better now!


    Neuroscientist Pengzhe (Paul) Lu has broken through a major set of obstacles facing SCI cure research. After years of painstaking work at the University of California, San Diego, Lu has largely reversed complete sub-acute SCI in rats with a combination of growth factors and neural stem cells embedded in a grafting gel. This is believed to be the first time in history that science has found a way to restore anything like this level of function in mammals with completely severed cords.
    “This opens the door,” Lu says, referring specifically to indicators that the new processes should also work well in humans. His findings were published in the Sep. 14 issue of the scientific journal, Cell.
    Lu’s approach is producing 200 times as many axons growing into the natural nervous tissue as previously achieved by any neuroscientist, according to Mark Tuszynski, of UCSD’s Department of Neurosciences’ Center for Neural Repair, and the study’s director. Axonal growth lengths are also 10 times longer than in the past, with “significant functional improvement” in the test animals.
    Recovery of motor function remains weak, however, and with poor coordination.
    “We do see a functional improvement,” Lu says. “It’s good, but it’s still not good enough,” he cautions — adding that the treated rats could not bear weight on their hind legs. He’s hard at work on a solution to this problem.
    It took six years of work just to develop the growth factor cocktail that produces this robust stem cell survival rate in the grafts. Other studies have produced some tantalizing levels of stem cell survival and even significant axonal growth, but these grafted stem cells are not merely surviving in small percentages — they are thriving, re-crafting their surroundings and reaching out to re-connect motor pathways effectively enough to produce full mobility at all joints in the animals’ hind legs.
    Lu characterized the results as “amazing” — a word used very sparingly by researchers and rightly held in great suspicion by those with SCI. But Lu is a 15-year T10-11 complete para himself (following an auto accident) — and he believes this is a significant breakthrough.
    read...
    http://www.spinalcord.org/breakthrou...-complete-sci/

  7. #847
    Paul Lu presented at our Summer Open House this past July, very impressive!

  8. #848
    Senior Member
    Join Date
    May 2005
    Location
    Pakistan
    Posts
    1,141
    Hope to see human trials soon

  9. #849
    Is it crazy to wonder why he wouldn't treat himself?

  10. #850
    StemCells, Inc. Interim Trial Data Show Motor Improvement in Patients With Cervical Spinal Cord Injury
    Positive Six-Month Results, With Gains in Both Strength and Motor Function, for the First Cohort in the Phase II Pathway Study
    0 0 0 61 /news-release/2015/11/18/788537/0/en/StemCells-Inc-Interim-Trial-Data-Show-Motor-Improvement-in-Patients-With-Cervical-Spinal-Cord-Injury.html?print=1 /news-release/2015/11/18/788537/0/en/StemCells-Inc-Interim-Trial-Data-Show-Motor-Improvement-in-Patients-With-Cervical-Spinal-Cord-Injury.html?print=1
    November 18, 2015 16:05 ET | Source: StemCells, Inc.
    NEWARK, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) showed motor improvements in both strength and function. The assessment of motor function involved using tests of dexterity.
    - See more at: http://globenewswire.com/news-releas....zwLtHa4R.dpuf

    http://globenewswire.com/news-releas...StemCells-Inc-

Similar Threads

  1. Replies: 0
    Last Post: 08-14-2005, 09:16 AM
  2. New articles posted to Research Forums.
    By Wise Young in forum Cure
    Replies: 1
    Last Post: 04-15-2004, 11:41 AM
  3. Replies: 0
    Last Post: 01-14-2004, 12:00 PM
  4. Replies: 8
    Last Post: 05-15-2003, 02:05 AM
  5. Replies: 1
    Last Post: 05-12-2002, 04:07 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •